Patent Term Extension Application for TEVIMBRA® (tislelizumab-jsgr), Patent No. 8,735,553 | Federal Regulations · Congress.wiki

Nonrulemaking

FDA

Open for Comments

FDA-2024-E-3572

Patent Term Extension Application for TEVIMBRA® (tislelizumab-jsgr), Patent No. 8,735,553

Documents

Comments

Description

Open

Comment Period OpensAug 9, 2024

Comment Period ClosesApr 28, 2026

Type	Title	Posted	Comments	Status
Notice	Determination of Regulatory Review Period for Purposes of Patent Extension; TEVIMBRA FR Doc: 2026-03851	Feb 26, 2026	--

CDER

Patent Term Extension Application

Patent No. 8,735,553

TEVIMBRA® (tislelizumab-jsgr)

BeiGene Switzerland GmbH

Foley & Lardner LLP

Open